The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

go back to reference Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SAA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712. https://doi.org/10.1001/jama.291.14.1701CrossRefPubMed Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SAA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712. https://​doi.​org/​10.​1001/​jama.​291.​14.​1701CrossRefPubMed

go back to reference Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112:130–134. https://doi.org/10.1002/ijc.20389CrossRefPubMed Bakken K, Alsaker E, Eggen AE, Lund E (2004) Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study. Int J Cancer 112:130–134. https://​doi.​org/​10.​1002/​ijc.​20389CrossRefPubMed

go back to reference Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hémon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw K-T, Olsen A, Tjønneland A, Rodriguez L, Sánchez M-J, Etxezarreta PA, Ardanaz E, Tormo M-J, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, González CA, Berrino F (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128:144–156. https://doi.org/10.1002/ijc.25314CrossRefPubMed Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hémon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw K-T, Olsen A, Tjønneland A, Rodriguez L, Sánchez M-J, Etxezarreta PA, Ardanaz E, Tormo M-J, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, González CA, Berrino F (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128:144–156. https://​doi.​org/​10.​1002/​ijc.​25314CrossRefPubMed

go back to reference Barcroft JF, Galazis N, Jones BP, Getreu N, Bracewell-Milnes T, Grewal KJ, Sorbi F, Yazbek J, Lathouras K, Smith JR, Hardiman P, Thum M-Y, Ben-Nagi J, Ghaem-Maghami S, Verbakel J, Saso S (2021) Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis. Hum Reprod 36:1093–1107. https://doi.org/10.1093/humrep/deaa293CrossRefPubMed Barcroft JF, Galazis N, Jones BP, Getreu N, Bracewell-Milnes T, Grewal KJ, Sorbi F, Yazbek J, Lathouras K, Smith JR, Hardiman P, Thum M-Y, Ben-Nagi J, Ghaem-Maghami S, Verbakel J, Saso S (2021) Fertility treatment and cancers-the eternal conundrum: a systematic review and meta-analysis. Hum Reprod 36:1093–1107. https://​doi.​org/​10.​1093/​humrep/​deaa293CrossRefPubMed

go back to reference Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427. https://doi.org/10.1016/s0140-6736(03)14065-2CrossRefPubMed Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427. https://​doi.​org/​10.​1016/​s0140-6736(03)14065-2CrossRefPubMed

go back to reference Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314. https://doi.org/10.1016/S0140-6736(08)60167-1CrossRefPubMed Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314. https://​doi.​org/​10.​1016/​S0140-6736(08)60167-1CrossRefPubMed

go back to reference Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842. https://doi.org/10.1016/s0140-6736(14)61687-1CrossRefPubMed Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842. https://​doi.​org/​10.​1016/​s0140-6736(14)61687-1CrossRefPubMed

go back to reference Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, Selby P, Howell A, Evans DG (2011) Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 105:22–27. https://doi.org/10.1038/bjc.2011.202CrossRefPubMedPubMedCentral Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, Selby P, Howell A, Evans DG (2011) Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 105:22–27. https://​doi.​org/​10.​1038/​bjc.​2011.​202CrossRefPubMedPubMedCentral

go back to reference Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, McNamee R, Elstein M, Kay C, Seif M, Buckley H (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360:2001–2008. https://doi.org/10.1016/s0140-6736(02)12001-0CrossRefPubMed Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, McNamee R, Elstein M, Kay C, Seif M, Buckley H (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360:2001–2008. https://​doi.​org/​10.​1016/​s0140-6736(02)12001-0CrossRefPubMed

go back to reference Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, Barrington W, Kuller LH, Simon MS, Lane D, Johnson KC, Rohan TE, Gass MLS, Cauley JA, Paskett ED, Sattari M, Prentice RL (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA 324:369–380. https://doi.org/10.1001/jama.2020.9482CrossRefPubMedPubMedCentral Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, Barrington W, Kuller LH, Simon MS, Lane D, Johnson KC, Rohan TE, Gass MLS, Cauley JA, Paskett ED, Sattari M, Prentice RL (2020) Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. JAMA 324:369–380. https://​doi.​org/​10.​1001/​jama.​2020.​9482CrossRefPubMedPubMedCentral

go back to reference Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16:631–650. https://doi.org/10.1093/humupd/dmq022CrossRefPubMed Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16:631–650. https://​doi.​org/​10.​1093/​humupd/​dmq022CrossRefPubMed

go back to reference Cibula D, Zikan M, Dusek L, Majek O (2011) Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 11:1197–1207. https://doi.org/10.1586/era.11.38CrossRefPubMed Cibula D, Zikan M, Dusek L, Majek O (2011) Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 11:1197–1207. https://​doi.​org/​10.​1586/​era.​11.​38CrossRefPubMed

go back to reference Clendenen TV, Kim S, Moy L, Wan L, Rusinek H, Stanczyk FZ, Pike MC, Zeleniuch-Jacquotte A (2013) Magnetic resonance imaging (MRI) of hormone-induced breast changes in young premenopausal women. Magn Reson Imaging 31:1–9. https://doi.org/10.1016/j.mri.2012.06.022CrossRefPubMed Clendenen TV, Kim S, Moy L, Wan L, Rusinek H, Stanczyk FZ, Pike MC, Zeleniuch-Jacquotte A (2013) Magnetic resonance imaging (MRI) of hormone-induced breast changes in young premenopausal women. Magn Reson Imaging 31:1–9. https://​doi.​org/​10.​1016/​j.​mri.​2012.​06.​022CrossRefPubMed

go back to reference Colditz GA, Stampfer MJ, Willett WC, Hunter DJ, Manson JE, Hennekens CH, Rosner BA, Speizer FE (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses’ Health Study. Cancer Causes Control 3:433–439. https://doi.org/10.1007/BF00051356CrossRefPubMed Colditz GA, Stampfer MJ, Willett WC, Hunter DJ, Manson JE, Hennekens CH, Rosner BA, Speizer FE (1992) Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses’ Health Study. Cancer Causes Control 3:433–439. https://​doi.​org/​10.​1007/​BF00051356CrossRefPubMed

go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394:1159–1168. https://doi.org/10.1016/S0140-6736(19)31709-XCrossRefPubMedCentral Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394:1159–1168. https://​doi.​org/​10.​1016/​S0140-6736(19)31709-XCrossRefPubMedCentral

go back to reference Collaborative Group on Hormonal Factors in Breast Cancer, van den Brandt PA, Goldbohm RA (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727. https://doi.org/10.1016/s0140-6736(96)90806-5CrossRef Collaborative Group on Hormonal Factors in Breast Cancer, van den Brandt PA, Goldbohm RA (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347:1713–1727. https://​doi.​org/​10.​1016/​s0140-6736(96)90806-5CrossRef

go back to reference de Jonge MM, Mooyaart AL, Vreeswijk MPG, de Kroon CD, van Wezel T, van Asperen CJ, Smit VTHBM, Dekkers OM, Bosse T (2017) Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: a meta-analysis and case report. Eur J Cancer 72:215–225. https://doi.org/10.1016/j.ejca.2016.11.028CrossRefPubMed de Jonge MM, Mooyaart AL, Vreeswijk MPG, de Kroon CD, van Wezel T, van Asperen CJ, Smit VTHBM, Dekkers OM, Bosse T (2017) Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: a meta-analysis and case report. Eur J Cancer 72:215–225. https://​doi.​org/​10.​1016/​j.​ejca.​2016.​11.​028CrossRefPubMed

go back to reference Dominguez-Valentin M, Sampson JR, Seppälä TT, ten Broeke SW, Plazzer J-P, Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A, Lopez-Köstner F, Gluck N, Katz LH, Heinimann K, Vaccaro CA, Büttner R, Görgens H, Holinski-Feder E, Morak M, Holzapfel S, Hüneburg R, von Knebel Doeberitz M, Loeffler M, Rahner N, Schackert HK, Steinke-Lange V, Schmiegel W, Vangala D, Pylvänäinen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C, Okkels H, Ketabi Z, Moreira L, Sánchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Möslein G, Mecklin J-P, Nielsen M, Møller P (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database. Genet Med 22:15–25. https://doi.org/10.1038/s41436-019-0596-9CrossRefPubMed Dominguez-Valentin M, Sampson JR, Seppälä TT, ten Broeke SW, Plazzer J-P, Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A, Lopez-Köstner F, Gluck N, Katz LH, Heinimann K, Vaccaro CA, Büttner R, Görgens H, Holinski-Feder E, Morak M, Holzapfel S, Hüneburg R, von Knebel Doeberitz M, Loeffler M, Rahner N, Schackert HK, Steinke-Lange V, Schmiegel W, Vangala D, Pylvänäinen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C, Okkels H, Ketabi Z, Moreira L, Sánchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Möslein G, Mecklin J-P, Nielsen M, Møller P (2020) Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database. Genet Med 22:15–25. https://​doi.​org/​10.​1038/​s41436-019-0596-9CrossRefPubMed

go back to reference Dominick S, Hickey M, Chin J, Su HI (2015) Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007245.pub3CrossRefPubMedPubMedCentral Dominick S, Hickey M, Chin J, Su HI (2015) Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. https://​doi.​org/​10.​1002/​14651858.​CD007245.​pub3CrossRefPubMedPubMedCentral

go back to reference Faubion SS, Kuhle CL, Shuster LT, Rocca WA (2015) Long-term health consequences of premature or early menopause and considerations for management. Climacteric 18:483–491. https://doi.org/10.3109/13697137.2015.1020484CrossRefPubMedPubMedCentral Faubion SS, Kuhle CL, Shuster LT, Rocca WA (2015) Long-term health consequences of premature or early menopause and considerations for management. Climacteric 18:483–491. https://​doi.​org/​10.​3109/​13697137.​2015.​1020484CrossRefPubMedPubMedCentral

go back to reference Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V (2023) Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis. PLoS Med 20:e1004188. https://doi.org/10.1371/journal.pmed.1004188CrossRefPubMedPubMedCentral Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V (2023) Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis. PLoS Med 20:e1004188. https://​doi.​org/​10.​1371/​journal.​pmed.​1004188CrossRefPubMedPubMedCentral

go back to reference Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454. https://doi.org/10.1002/ijc.20710CrossRefPubMed Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454. https://​doi.​org/​10.​1002/​ijc.​20710CrossRefPubMed

go back to reference Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111. https://doi.org/10.1007/s10549-007-9523-xCrossRefPubMed Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111. https://​doi.​org/​10.​1007/​s10549-007-9523-xCrossRefPubMed

go back to reference Gaba F, Manchanda R (2020) Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best Pract Res Clin Obstet Gynaecol 65:46–65. https://doi.org/10.1016/j.bpobgyn.2020.01.006CrossRefPubMed Gaba F, Manchanda R (2020) Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best Pract Res Clin Obstet Gynaecol 65:46–65. https://​doi.​org/​10.​1016/​j.​bpobgyn.​2020.​01.​006CrossRefPubMed

go back to reference Gabrielson M, Azam S, Hardell E, Holm M, Ubhayasekera KA, Eriksson M, Bäcklund M, Bergquist J, Czene K, Hall P (2020) Hormonal determinants of mammographic density and density change. Breast Cancer Res 22:95. https://doi.org/10.1186/s13058-020-01332-4CrossRefPubMedPubMedCentral Gabrielson M, Azam S, Hardell E, Holm M, Ubhayasekera KA, Eriksson M, Bäcklund M, Bergquist J, Czene K, Hall P (2020) Hormonal determinants of mammographic density and density change. Breast Cancer Res 22:95. https://​doi.​org/​10.​1186/​s13058-020-01332-4CrossRefPubMedPubMedCentral

go back to reference Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET (2019) Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis. Psychoneuroendocrinology 106:9–19. https://doi.org/10.1016/j.psyneuen.2019.03.013CrossRefPubMed Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET (2019) Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis. Psychoneuroendocrinology 106:9–19. https://​doi.​org/​10.​1016/​j.​psyneuen.​2019.​03.​013CrossRefPubMed

go back to reference Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J (2016) Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril 105:781–785. https://doi.org/10.1016/j.fertnstert.2015.11.034CrossRefPubMed Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J (2016) Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertil Steril 105:781–785. https://​doi.​org/​10.​1016/​j.​fertnstert.​2015.​11.​034CrossRefPubMed

go back to reference Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ (2010) Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ 340:c927. https://doi.org/10.1136/bmj.c927CrossRefPubMedPubMedCentral Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ (2010) Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ 340:c927. https://​doi.​org/​10.​1136/​bmj.​c927CrossRefPubMedPubMedCentral

go back to reference Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP (2001) Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135:939–953. https://doi.org/10.7326/0003-4819-135-11-200112040-00005CrossRefPubMed Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP (2001) Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 135:939–953. https://​doi.​org/​10.​7326/​0003-4819-135-11-200112040-00005CrossRefPubMed

go back to reference Huber D, Seitz S, Kast K, Emons G, Ortmann O (2020a) Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 302:715–720. https://doi.org/10.1007/s00404-020-05690-4CrossRefPubMedPubMedCentral Huber D, Seitz S, Kast K, Emons G, Ortmann O (2020a) Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 302:715–720. https://​doi.​org/​10.​1007/​s00404-020-05690-4CrossRefPubMedPubMedCentral

go back to reference Huber D, Seitz S, Kast K, Emons G, Ortmann O (2020b) Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 301:875–884. https://doi.org/10.1007/s00404-020-05458-wCrossRefPubMedPubMedCentral Huber D, Seitz S, Kast K, Emons G, Ortmann O (2020b) Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 301:875–884. https://​doi.​org/​10.​1007/​s00404-020-05458-wCrossRefPubMedPubMedCentral

go back to reference Huber D, Seitz S, Kast K, Emons G, Ortmann O (2021) Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. J Cancer Res Clin Oncol 147:2035–2045. https://doi.org/10.1007/s00432-021-03629-zCrossRefPubMedPubMedCentral Huber D, Seitz S, Kast K, Emons G, Ortmann O (2021) Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. J Cancer Res Clin Oncol 147:2035–2045. https://​doi.​org/​10.​1007/​s00432-021-03629-zCrossRefPubMedPubMedCentral

go back to reference Jensen A, Sharif H, Frederiksen K, Kjaer SK (2009) Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 338:b249. https://doi.org/10.1136/bmj.b249CrossRefPubMedPubMedCentral Jensen A, Sharif H, Frederiksen K, Kjaer SK (2009) Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 338:b249. https://​doi.​org/​10.​1136/​bmj.​b249CrossRefPubMedPubMedCentral

go back to reference Kessous R, Davidson E, Meirovitz M, Sergienko R, Sheiner E (2016) The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol 142:287–293. https://doi.org/10.1007/s00432-015-2035-xCrossRefPubMed Kessous R, Davidson E, Meirovitz M, Sergienko R, Sheiner E (2016) The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol 142:287–293. https://​doi.​org/​10.​1007/​s00432-015-2035-xCrossRefPubMed

go back to reference Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101:1364–1371. https://doi.org/10.1210/jc.2015-3878CrossRefPubMedPubMedCentral Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101:1364–1371. https://​doi.​org/​10.​1210/​jc.​2015-3878CrossRefPubMedPubMedCentral

go back to reference Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B, Sun P, Narod SA (2006) Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100:83–88. https://doi.org/10.1016/j.ygyno.2005.07.110CrossRefPubMed Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B, Sun P, Narod SA (2006) Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100:83–88. https://​doi.​org/​10.​1016/​j.​ygyno.​2005.​07.​110CrossRefPubMed

go back to reference Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Randall S, Manoukian S, Pasini B, Tung N, Ainsworth PJ, Cummings S, Sun P, Narod SA (2008) Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 19:1111–1119. https://doi.org/10.1007/s10552-008-9175-0CrossRefPubMed Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, Lynch HT, Moller P, Foulkes WD, Randall S, Manoukian S, Pasini B, Tung N, Ainsworth PJ, Cummings S, Sun P, Narod SA (2008) Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 19:1111–1119. https://​doi.​org/​10.​1007/​s10552-008-9175-0CrossRefPubMed

go back to reference Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA (2016) Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat 155:365–373. https://doi.org/10.1007/s10549-016-3685-3CrossRefPubMed Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA (2016) Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat 155:365–373. https://​doi.​org/​10.​1007/​s10549-016-3685-3CrossRefPubMed

go back to reference Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA (2018) Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol 4:1059–1065. https://doi.org/10.1001/jamaoncol.2018.0211CrossRefPubMedPubMedCentral Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA (2018) Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol 4:1059–1065. https://​doi.​org/​10.​1001/​jamaoncol.​2018.​0211CrossRefPubMedPubMedCentral

go back to reference Laitman Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, Reish O, Josefsberg Ben-Yehoshua S, Bernstein-Molho R, Keinan-Boker L, Rosengarten O, Silverman BG, Perri T, Korach J, Mor P, Ephrat Ben-Baruch N, Levy Lahad E, Friedman E (2019) Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. Cancer 125:698–703. https://doi.org/10.1002/cncr.31842CrossRefPubMed Laitman Y, Michaelson-Cohen R, Levi E, Chen-Shtoyerman R, Reish O, Josefsberg Ben-Yehoshua S, Bernstein-Molho R, Keinan-Boker L, Rosengarten O, Silverman BG, Perri T, Korach J, Mor P, Ephrat Ben-Baruch N, Levy Lahad E, Friedman E (2019) Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers. Cancer 125:698–703. https://​doi.​org/​10.​1002/​cncr.​31842CrossRefPubMed

go back to reference Lando JF, Heck KE, Brett KM (1999) Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med 17:176–180. https://doi.org/10.1016/s0749-3797(99)00078-1CrossRefPubMed Lando JF, Heck KE, Brett KM (1999) Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med 17:176–180. https://​doi.​org/​10.​1016/​s0749-3797(99)00078-1CrossRefPubMed

go back to reference Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izquierdo A, Simard J, Schmidt MK, Walter FM, Chatterjee N, Garcia-Closas M, Tischkowitz M, Pharoah P, Easton DF, Antoniou AC (2019) BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 21:1708–1718. https://doi.org/10.1038/s41436-018-0406-9CrossRefPubMedPubMedCentral Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izquierdo A, Simard J, Schmidt MK, Walter FM, Chatterjee N, Garcia-Closas M, Tischkowitz M, Pharoah P, Easton DF, Antoniou AC (2019) BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 21:1708–1718. https://​doi.​org/​10.​1038/​s41436-018-0406-9CrossRefPubMedPubMedCentral

go back to reference Liu X, Yue J, Pervaiz R, Zhang H, Wang L (2022) Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:986477. https://doi.org/10.3389/fendo.2022.986477CrossRefPubMed Liu X, Yue J, Pervaiz R, Zhang H, Wang L (2022) Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:986477. https://​doi.​org/​10.​3389/​fendo.​2022.​986477CrossRefPubMed

go back to reference Liu J, Jin X, Liu W, Chen W, Wang L, Feng Z, Huang J (2023) The risk of long-term cardiometabolic disease in women with premature or early menopause: a systematic review and meta-analysis. Front Cardiovasc Med 10:1131251. https://doi.org/10.3389/fcvm.2023.1131251CrossRefPubMedPubMedCentral Liu J, Jin X, Liu W, Chen W, Wang L, Feng Z, Huang J (2023) The risk of long-term cardiometabolic disease in women with premature or early menopause: a systematic review and meta-analysis. Front Cardiovasc Med 10:1131251. https://​doi.​org/​10.​3389/​fcvm.​2023.​1131251CrossRefPubMedPubMedCentral

go back to reference Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M (2007) Hormone replacement therapy and breast cancer in former users of oral contraceptives–The Norwegian Women and Cancer study. Int J Cancer 121:645–648. https://doi.org/10.1002/ijc.22699CrossRefPubMed Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M (2007) Hormone replacement therapy and breast cancer in former users of oral contraceptives–The Norwegian Women and Cancer study. Int J Cancer 121:645–648. https://​doi.​org/​10.​1002/​ijc.​22699CrossRefPubMed

go back to reference Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19:237–243. https://doi.org/10.1097/EDE.0b013e31816334c5CrossRefPubMed Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19:237–243. https://​doi.​org/​10.​1097/​EDE.​0b013e31816334c5​CrossRefPubMed

go back to reference Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–1368. https://doi.org/10.1001/jama.2013.278040CrossRefPubMed Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310:1353–1368. https://​doi.​org/​10.​1001/​jama.​2013.​278040CrossRefPubMed

go back to reference Marchetti C, de Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P (2018) Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit Rev Oncol Hematol 132:111–115. https://doi.org/10.1016/j.critrevonc.2018.09.018CrossRefPubMed Marchetti C, de Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P (2018) Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Crit Rev Oncol Hematol 132:111–115. https://​doi.​org/​10.​1016/​j.​critrevonc.​2018.​09.​018CrossRefPubMed

go back to reference McCormack VA, dos Santos SI (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159–1169. https://doi.org/10.1158/1055-9965.EPI-06-0034CrossRefPubMed McCormack VA, dos Santos SI (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:1159–1169. https://​doi.​org/​10.​1158/​1055-9965.​EPI-06-0034CrossRefPubMed

go back to reference Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S (2021) Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer 148:95–102. https://doi.org/10.1016/j.ejca.2021.02.007CrossRefPubMed Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S (2021) Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer 148:95–102. https://​doi.​org/​10.​1016/​j.​ejca.​2021.​02.​007CrossRefPubMed

go back to reference Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, Berchuck A, Schildkraut JM (2008) Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 167:1059–1069. https://doi.org/10.1093/aje/kwn006CrossRefPubMed Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, Berchuck A, Schildkraut JM (2008) Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 167:1059–1069. https://​doi.​org/​10.​1093/​aje/​kwn006CrossRefPubMed

go back to reference Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 31:4188–4198. https://doi.org/10.1200/JCO.2013.48.9021CrossRefPubMed Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 31:4188–4198. https://​doi.​org/​10.​1200/​JCO.​2013.​48.​9021CrossRefPubMed

go back to reference Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø (2017) Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 377:2228–2239. https://doi.org/10.1056/NEJMoa1700732CrossRefPubMed Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø (2017) Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 377:2228–2239. https://​doi.​org/​10.​1056/​NEJMoa1700732CrossRefPubMed

go back to reference Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O (2018) Contemporary hormonal contraception and the risk of breast cancer. ESPE. https://doi.org/10.1530/ey.15.15.9CrossRef Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O (2018) Contemporary hormonal contraception and the risk of breast cancer. ESPE. https://​doi.​org/​10.​1530/​ey.​15.​15.​9CrossRef

go back to reference Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol 113:1027–1037. https://doi.org/10.1097/AOG.0b013e3181a11c64CrossRefPubMedPubMedCentral Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol 113:1027–1037. https://​doi.​org/​10.​1097/​AOG.​0b013e3181a11c64​CrossRefPubMedPubMedCentral

go back to reference Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121:709–716. https://doi.org/10.1097/AOG.0b013e3182864350CrossRefPubMedPubMedCentral Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE (2013) Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 121:709–716. https://​doi.​org/​10.​1097/​AOG.​0b013e3182864350​CrossRefPubMedPubMedCentral

go back to reference Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, Friedman E, Korach J (2015) Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril 103:1305–1312. https://doi.org/10.1016/j.fertnstert.2015.02.011CrossRefPubMed Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, Friedman E, Korach J (2015) Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril 103:1305–1312. https://​doi.​org/​10.​1016/​j.​fertnstert.​2015.​02.​011CrossRefPubMed

go back to reference Perri T, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J (2021) Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. Fertil Steril 116(2):538–545. https://doi.org/10.1016/j.fertnstert.2021.02.030CrossRefPubMed Perri T, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J (2021) Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. Fertil Steril 116(2):538–545. https://​doi.​org/​10.​1016/​j.​fertnstert.​2021.​02.​030CrossRefPubMed

go back to reference Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170:12–23. https://doi.org/10.1093/aje/kwp115CrossRefPubMedPubMedCentral Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE (2009) Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170:12–23. https://​doi.​org/​10.​1093/​aje/​kwp115CrossRefPubMedPubMedCentral

go back to reference Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JE (2021) Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50–59 years of age. Am J Epidemiol 190:365–375. https://doi.org/10.1093/aje/kwaa210CrossRefPubMed Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, Wactawski-Wende J, Kuller LH, Wallace R, Johnson KC, Shadyab AH, Gass M, Manson JE (2021) Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50–59 years of age. Am J Epidemiol 190:365–375. https://​doi.​org/​10.​1093/​aje/​kwaa210CrossRefPubMed

go back to reference Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van Veer ‘t L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810. https://doi.org/10.1200/JCO.2004.00.8151CrossRefPubMed Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van Veer ‘t L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810. https://​doi.​org/​10.​1200/​JCO.​2004.​00.​8151CrossRefPubMed

go back to reference Rizzuto I, Behrens RF, Smith LA (2019) Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev. 6:CD008215. https://doi.org/10.1002/14651858.CD008215.pub3CrossRefPubMed Rizzuto I, Behrens RF, Smith LA (2019) Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev. 6:CD008215. https://​doi.​org/​10.​1002/​14651858.​CD008215.​pub3CrossRefPubMed

go back to reference Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7:821–828. https://doi.org/10.1016/S1470-2045(06)70869-5CrossRefPubMed Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7:821–828. https://​doi.​org/​10.​1016/​S1470-2045(06)70869-5CrossRefPubMed

go back to reference SS3-Guideline “Diagnosis, Treatment and Follow-up of malignant Ovarian Tumors”: AWMF-Registrynumber: 032/035, long version. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/LL_Ovarialkarzinom_Langversion_5.1.pdf. Accessed 26 March 2024 SS3-Guideline “Diagnosis, Treatment and Follow-up of malignant Ovarian Tumors”: AWMF-Registrynumber: 032/035, long version. https://​www.​leitlinienprogra​mm-onkologie.​de/​fileadmin/​user_​upload/​LL_​Ovarialkarzinom_​Langversion_​5.​1.​pdf. Accessed 26 March 2024

go back to reference S3-Guideline “Endometrial Cancer”: AWMF-Registrynumber 032/034-OL, long version 2.0, September 2022. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Endometriumkarzinom/Version_2/LL_Endometriumkarzinom_Langversion_2.0.pdf. Accessed 3 May 2024 S3-Guideline “Endometrial Cancer”: AWMF-Registrynumber 032/034-OL, long version 2.0, September 2022. https://​www.​leitlinienprogra​mm-onkologie.​de/​fileadmin/​user_​upload/​Downloads/​Leitlinien/​Endometriumkarzi​nom/​Version_​2/​LL_​Endometriumkarzi​nom_​Langversion_​2.​0.​pdf. Accessed 3 May 2024

go back to reference S3-Guideline “Hormonal Contraception”: AWMF-Registrynumber 015/015, September 2020, Version 1.2. https://register.awmf.org/assets/guidelines/015-015l_S3_Hormonelle_Empfaengnisverhuetung_2020-09.pdf. Accessed 3 May 2024 S3-Guideline “Hormonal Contraception”: AWMF-Registrynumber 015/015, September 2020, Version 1.2. https://​register.​awmf.​org/​assets/​guidelines/​015-015l_​S3_​Hormonelle_​Empfaengnisverhu​etung_​2020-09.​pdf. Accessed 3 May 2024

go back to reference S3-Guideline “Peri- and Postmenopause—Diagnosis and Interventions: Guideline of the German Society of Gynecology and Obstetrics (S-3 Level, AWMF Registry No. 015–062); October 2018. http://www.awmf.org/leitlinien/detail/ll/015-062.html. Accessed 27 November 2021 S3-Guideline “Peri- and Postmenopause—Diagnosis and Interventions: Guideline of the German Society of Gynecology and Obstetrics (S-3 Level, AWMF Registry No. 015–062); October 2018. http://​www.​awmf.​org/​leitlinien/​detail/​ll/​015-062.​html. Accessed 27 November 2021

go back to reference S3-Guideline “Screening, Diagnosis, Treatment and Follow-up of Breast Cancer”: AWMF-Registrynumber: 032–045, long version, Version 4.4, June 2021. https://register.awmf.org/assets/guidelines/032-045OLl_S3_Mammakarzinom_2021-07.pdf. Accessed 26.03.24 S3-Guideline “Screening, Diagnosis, Treatment and Follow-up of Breast Cancer”: AWMF-Registrynumber: 032–045, long version, Version 4.4, June 2021. https://​register.​awmf.​org/​assets/​guidelines/​032-045OLl_​S3_​Mammakarzinom_​2021-07.​pdf. Accessed 26.03.24

go back to reference Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D, Bernstein L, Ursin G (2010) Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 19:2366–2378. https://doi.org/10.1158/1055-9965.EPI-10-0162CrossRefPubMedPubMedCentral Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D, Bernstein L, Ursin G (2010) Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 19:2366–2378. https://​doi.​org/​10.​1158/​1055-9965.​EPI-10-0162CrossRefPubMedPubMedCentral

go back to reference Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485–491. https://doi.org/10.1001/jama.283.4.485CrossRefPubMed Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485–491. https://​doi.​org/​10.​1001/​jama.​283.​4.​485CrossRefPubMed

go back to reference Schrijver LH, Olsson H, Phillips K-A, Terry MB, Goldgar DE, Kast K, Engel C, Mooij TM, Adlard J, Barrowdale D, Davidson R, Eeles R, Ellis S, Evans DG, Frost D, Izatt L, Porteous ME, Side LE, Walker L, Berthet P, Bonadona V, Leroux D, Mouret-Fourme E, Venat-Bouvet L, Buys SS, Southey MC, John EM, Chung WK, Daly MB, Bane A, van Asperen CJ, Gómez Garcia EB, Mourits MJE, van Os TAM, Roos-Blom M-J, Friedlander ML, McLachlan S-A, Singer CF, Tan YY, Foretova L, Navratilova M, Gerdes A-M, Caldes T, Simard J, Olah E, Jakubowska A, Arver B, Osorio A, Noguès C, Andrieu N, Easton DF, van Leeuwen FE, Hopper JL, Milne RL, Antoniou AC, Rookus MA (2018) Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study. JNCI Cancer Spectr. 2:023. https://doi.org/10.1093/jncics/pky023CrossRef Schrijver LH, Olsson H, Phillips K-A, Terry MB, Goldgar DE, Kast K, Engel C, Mooij TM, Adlard J, Barrowdale D, Davidson R, Eeles R, Ellis S, Evans DG, Frost D, Izatt L, Porteous ME, Side LE, Walker L, Berthet P, Bonadona V, Leroux D, Mouret-Fourme E, Venat-Bouvet L, Buys SS, Southey MC, John EM, Chung WK, Daly MB, Bane A, van Asperen CJ, Gómez Garcia EB, Mourits MJE, van Os TAM, Roos-Blom M-J, Friedlander ML, McLachlan S-A, Singer CF, Tan YY, Foretova L, Navratilova M, Gerdes A-M, Caldes T, Simard J, Olah E, Jakubowska A, Arver B, Osorio A, Noguès C, Andrieu N, Easton DF, van Leeuwen FE, Hopper JL, Milne RL, Antoniou AC, Rookus MA (2018) Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study. JNCI Cancer Spectr. 2:023. https://​doi.​org/​10.​1093/​jncics/​pky023CrossRef

go back to reference Schrijver LH, Antoniou AC, Olsson H, Mooij TM, Roos-Blom M-J, Azarang L, Adlard J, Ahmed M, Barrowdale D, Davidson R, Donaldson A, Eeles R, Evans DG, Frost D, Henderson A, Izatt L, Ong K-R, Bonadona V, Coupier I, Faivre L, Fricker J-P, Gesta P, van Engelen K, Jager A, Menko FH, Mourits MJE, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes A-M, Caldes T, Simard J, Olah E, Jakubowska A, Rantala J, Osorio A, Hopper JL, Phillips K-A, Milne RL, Beth Terry M, Noguès C, Engel C, Kast K, Goldgar DE, van Leeuwen FE, Easton DF, Andrieu N, Rookus MA (2021) Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol 225:51.e1-51.e17. https://doi.org/10.1016/j.ajog.2021.01.014CrossRefPubMed Schrijver LH, Antoniou AC, Olsson H, Mooij TM, Roos-Blom M-J, Azarang L, Adlard J, Ahmed M, Barrowdale D, Davidson R, Donaldson A, Eeles R, Evans DG, Frost D, Henderson A, Izatt L, Ong K-R, Bonadona V, Coupier I, Faivre L, Fricker J-P, Gesta P, van Engelen K, Jager A, Menko FH, Mourits MJE, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes A-M, Caldes T, Simard J, Olah E, Jakubowska A, Rantala J, Osorio A, Hopper JL, Phillips K-A, Milne RL, Beth Terry M, Noguès C, Engel C, Kast K, Goldgar DE, van Leeuwen FE, Easton DF, Andrieu N, Rookus MA (2021) Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol 225:51.e1-51.e17. https://​doi.​org/​10.​1016/​j.​ajog.​2021.​01.​014CrossRefPubMed

go back to reference Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips K-A, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA (2022) Oral contraceptive use in BRCA1 and BRCA2 mutation carriers: absolute cancer risks and benefits. J Natl Cancer Inst 114:540–552. https://doi.org/10.1093/jnci/djac004CrossRefPubMedPubMedCentral Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips K-A, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA (2022) Oral contraceptive use in BRCA1 and BRCA2 mutation carriers: absolute cancer risks and benefits. J Natl Cancer Inst 114:540–552. https://​doi.​org/​10.​1093/​jnci/​djac004CrossRefPubMedPubMedCentral

go back to reference Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA (2013) The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 130:127–131. https://doi.org/10.1016/j.ygyno.2013.03.027CrossRefPubMed Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA (2013) The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 130:127–131. https://​doi.​org/​10.​1016/​j.​ygyno.​2013.​03.​027CrossRefPubMed

go back to reference Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA (2015) Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Fam Cancer 14:383–391. https://doi.org/10.1007/s10689-015-9798-8CrossRefPubMedPubMedCentral Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA (2015) Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Fam Cancer 14:383–391. https://​doi.​org/​10.​1007/​s10689-015-9798-8CrossRefPubMedPubMedCentral

go back to reference Sergentanis TN, Diamantaras A-A, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET (2014) IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update 20:106–123. https://doi.org/10.1093/humupd/dmt034CrossRefPubMed Sergentanis TN, Diamantaras A-A, Perlepe C, Kanavidis P, Skalkidou A, Petridou ET (2014) IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update 20:106–123. https://​doi.​org/​10.​1093/​humupd/​dmt034CrossRefPubMed

go back to reference Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND (2016) Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2:1434–1440. https://doi.org/10.1001/jamaoncol.2016.1820CrossRefPubMedPubMedCentral Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND (2016) Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2:1434–1440. https://​doi.​org/​10.​1001/​jamaoncol.​2016.​1820CrossRefPubMedPubMedCentral

go back to reference Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET (2013) Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer–a systematic review and meta-analysis. Hum Reprod Update 19:105–123. https://doi.org/10.1093/humupd/dms051CrossRefPubMed Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET (2013) Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer–a systematic review and meta-analysis. Hum Reprod Update 19:105–123. https://​doi.​org/​10.​1093/​humupd/​dms051CrossRefPubMed

go back to reference Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E (2016) Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube. Acta Oncol 55:1281–1284. https://doi.org/10.1080/0284186X.2016.1175660CrossRefPubMed Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E (2016) Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube. Acta Oncol 55:1281–1284. https://​doi.​org/​10.​1080/​0284186X.​2016.​1175660CrossRefPubMed

go back to reference Sourander L, Rajala T, Räihä I, Mäkinen J, Erkkola R, Helenius H (1998) Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352:1965–1969. https://doi.org/10.1016/S0140-6736(98)05066-1CrossRefPubMed Sourander L, Rajala T, Räihä I, Mäkinen J, Erkkola R, Helenius H (1998) Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 352:1965–1969. https://​doi.​org/​10.​1016/​S0140-6736(98)05066-1CrossRefPubMed

go back to reference Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottesen B (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109:721–727. https://doi.org/10.1002/ijc.20016CrossRefPubMed Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottesen B (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109:721–727. https://​doi.​org/​10.​1002/​ijc.​20016CrossRefPubMed

go back to reference Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA (2020) Menopausal hormone therapy and risk of endometrial cancer: a systematic review. Cancers. https://doi.org/10.3390/cancers12082195CrossRefPubMedPubMedCentral Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA (2020) Menopausal hormone therapy and risk of endometrial cancer: a systematic review. Cancers. https://​doi.​org/​10.​3390/​cancers12082195CrossRefPubMedPubMedCentral

go back to reference Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365. https://doi.org/10.1093/jnci/94.18.1358CrossRefPubMed Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365. https://​doi.​org/​10.​1093/​jnci/​94.​18.​1358CrossRefPubMed

go back to reference Tjønneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Mellemkjaer L (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100:2328–2337. https://doi.org/10.1002/cncr.20250CrossRefPubMed Tjønneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Mellemkjaer L (2004) Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100:2328–2337. https://​doi.​org/​10.​1002/​cncr.​20250CrossRefPubMed

go back to reference van Bommel MHD, IntHout J, Veldmate G, Kets CM, de Hullu JA, van Altena AM, Harmsen MG (2023) Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum Reprod Update 29:197–217. https://doi.org/10.1093/humupd/dmac038CrossRefPubMed van Bommel MHD, IntHout J, Veldmate G, Kets CM, de Hullu JA, van Altena AM, Harmsen MG (2023) Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum Reprod Update 29:197–217. https://​doi.​org/​10.​1093/​humupd/​dmac038CrossRefPubMed

go back to reference van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JSE, van Santbrink EJP, van der Westerlaken LAJ, Cohlen BJ, Braat DDM, Smeenk JMJ, Land JA, Goddijn M, van Golde RJT, van Rumste MM, Schats R, Józwiak K, Hauptmann M, Rookus MA, Burger CW, van Leeuwen FE (2016) Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA 316:300–312. https://doi.org/10.1001/jama.2016.9389CrossRefPubMed van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JSE, van Santbrink EJP, van der Westerlaken LAJ, Cohlen BJ, Braat DDM, Smeenk JMJ, Land JA, Goddijn M, van Golde RJT, van Rumste MM, Schats R, Józwiak K, Hauptmann M, Rookus MA, Burger CW, van Leeuwen FE (2016) Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA 316:300–312. https://​doi.​org/​10.​1001/​jama.​2016.​9389CrossRefPubMed

go back to reference van der Klift M, de Laet CEDH, McCloskey EV, Johnell O, Kanis JA, Hofman A, Pols HAP (2004) Risk factors for incident vertebral fractures in men and women: the Rotterdam study. J Bone Miner Res 19:1172–1180. https://doi.org/10.1359/JBMR.040215CrossRefPubMed van der Klift M, de Laet CEDH, McCloskey EV, Johnell O, Kanis JA, Hofman A, Pols HAP (2004) Risk factors for incident vertebral fractures in men and women: the Rotterdam study. J Bone Miner Res 19:1172–1180. https://​doi.​org/​10.​1359/​JBMR.​040215CrossRefPubMed

go back to reference Vega EM, Egea MA, Mautalen CA (1994) Influence of the menopausal age on the severity of osteoporosis in women with vertebral fractures. Maturitas 19:117–124. https://doi.org/10.1016/0378-5122(94)90061-2CrossRefPubMed Vega EM, Egea MA, Mautalen CA (1994) Influence of the menopausal age on the severity of osteoporosis in women with vertebral fractures. Maturitas 19:117–124. https://​doi.​org/​10.​1016/​0378-5122(94)90061-2CrossRefPubMed

go back to reference Vermeulen RFM, van Beurden M, Korse CM, Kenter GG (2017) Impact of risk-reducing salpingo-oophorectomy in premenopausal women. Climacteric 20:212–221. https://doi.org/10.1080/13697137.2017.1285879CrossRefPubMed Vermeulen RFM, van Beurden M, Korse CM, Kenter GG (2017) Impact of risk-reducing salpingo-oophorectomy in premenopausal women. Climacteric 20:212–221. https://​doi.​org/​10.​1080/​13697137.​2017.​1285879CrossRefPubMed

go back to reference Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243–1249. https://doi.org/10.1056/NEJMoa010534CrossRefPubMed Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243–1249. https://​doi.​org/​10.​1056/​NEJMoa010534CrossRefPubMed

go back to reference Willis DB, Calle EE, Miracle-McMahill HL, Heath CW (1996) Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7:449–457. https://doi.org/10.1007/BF00052671CrossRefPubMed Willis DB, Calle EE, Miracle-McMahill HL, Heath CW (1996) Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7:449–457. https://​doi.​org/​10.​1007/​BF00052671CrossRefPubMed

go back to reference Xia YY, Gronwald J, Karlan B, Lubinski J, McCuaig JM, Brooks J, Moller P, Eisen A, Sun S, Senter L, Bordeleau L, Neuhausen SL, Singer CF, Tung N, Foulkes WD, Sun P, Narod SA, Kotsopoulos J (2022) Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 164:514–521. https://doi.org/10.1016/j.ygyno.2022.01.014CrossRefPubMed Xia YY, Gronwald J, Karlan B, Lubinski J, McCuaig JM, Brooks J, Moller P, Eisen A, Sun S, Senter L, Bordeleau L, Neuhausen SL, Singer CF, Tung N, Foulkes WD, Sun P, Narod SA, Kotsopoulos J (2022) Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 164:514–521. https://​doi.​org/​10.​1016/​j.​ygyno.​2022.​01.​014CrossRefPubMed